Is IMRX or JANX more profitable?

Janux Therapeutics' return on equity of -11.89% beat Immuneering's return on equity. Company Net Margins Return on Equity Return on Assets Immuneering N/A -27.15% -25.75% Janux Therapeutics N/A -11.89% -11.13%

Does the media refer more to IMRX or JANX?

In the previous week, Immuneering had 2 more articles in the media than Janux Therapeutics. MarketBeat recorded 6 mentions for Immuneering and 4 mentions for Janux Therapeutics. Janux Therapeutics' average media sentiment score of 1.36 beat Immuneering's score of -0.32 indicating that Janux Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immuneering 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 3 Very Negative mention(s) Neutral Janux Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to IMRX or GLUE?

In the previous week, Monte Rosa Therapeutics had 2 more articles in the media than Immuneering. MarketBeat recorded 8 mentions for Monte Rosa Therapeutics and 6 mentions for Immuneering. Monte Rosa Therapeutics' average media sentiment score of 0.84 beat Immuneering's score of -0.32 indicating that Monte Rosa Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immuneering 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 3 Very Negative mention(s) Neutral Monte Rosa Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation and earnings, IMRX or CRVS?

Corvus Pharmaceuticals is trading at a lower price-to-earnings ratio than Immuneering, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Immuneering N/A N/A -$56.03M -$1.04 N/A Corvus Pharmaceuticals N/A N/A -$15.28M -$0.61 N/A

Is IMRX or CRVS more profitable?

Immuneering's return on equity of -27.15% beat Corvus Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Immuneering N/A -27.15% -25.75% Corvus Pharmaceuticals N/A -36.15% -33.62%

Does the media favor IMRX or CRVS?

In the previous week, Immuneering had 4 more articles in the media than Corvus Pharmaceuticals. MarketBeat recorded 6 mentions for Immuneering and 2 mentions for Corvus Pharmaceuticals. Corvus Pharmaceuticals' average media sentiment score of 1.70 beat Immuneering's score of -0.32 indicating that Corvus Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immuneering 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 3 Very Negative mention(s) Neutral Corvus Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has stronger earnings & valuation, SVRA or IMRX?

Savara is trading at a lower price-to-earnings ratio than Immuneering, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Savara N/A N/A -$118.84M -$0.58 N/A Immuneering N/A N/A -$56.03M -$1.04 N/A

Is SVRA or IMRX more profitable?

Immuneering's return on equity of -27.15% beat Savara's return on equity. Company Net Margins Return on Equity Return on Assets Savara N/A -90.28% -68.95% Immuneering N/A -27.15% -25.75%

Does the media prefer SVRA or IMRX?

In the previous week, Immuneering had 4 more articles in the media than Savara. MarketBeat recorded 6 mentions for Immuneering and 2 mentions for Savara. Savara's average media sentiment score of 1.84 beat Immuneering's score of -0.32 indicating that Savara is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Savara 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Immuneering 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 3 Very Negative mention(s) Neutral

Does the media prefer IMRX or KURA?

In the previous week, Kura Oncology had 2 more articles in the media than Immuneering. MarketBeat recorded 8 mentions for Kura Oncology and 6 mentions for Immuneering. Kura Oncology's average media sentiment score of 0.43 beat Immuneering's score of -0.32 indicating that Kura Oncology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immuneering 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 3 Very Negative mention(s) Neutral Kura Oncology 1 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Immuneering (IMRX) Competitors

$4.27 -0.30 (-6.56%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$4.34 +0.07 (+1.52%)

As of 09/11/2026 07:30 PM Eastern

Compare

IMRX vs. JANX, GLUE, CRVS, SVRA, and KURA

Should you buy Immuneering stock or one of its competitors? Immuneering's main competitors and comparable companies include Janux Therapeutics (JANX), Monte Rosa Therapeutics (GLUE), Corvus Pharmaceuticals (CRVS), Savara (SVRA), and Kura Oncology (KURA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Immuneering compare to Janux Therapeutics?

Immuneering (NASDAQ:IMRX) and Janux Therapeutics (NASDAQ:JANX) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, valuation, media sentiment, risk, earnings, analyst recommendations, dividends and institutional ownership.

Immuneering has higher earnings, but lower revenue than Janux Therapeutics. Janux Therapeutics is trading at a lower price-to-earnings ratio than Immuneering, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immuneering	N/A	N/A	-$56.03M	-$1.04	N/A
Janux Therapeutics	$10M	104.55	-$113.62M	-$1.64	N/A

Janux Therapeutics' return on equity of -11.89% beat Immuneering's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immuneering	N/A	-27.15%	-25.75%
Janux Therapeutics	N/A	-11.89%	-11.13%

Immuneering presently has a consensus price target of $17.50, indicating a potential upside of 309.84%. Janux Therapeutics has a consensus price target of $36.46, indicating a potential upside of 113.23%. Given Immuneering's stronger consensus rating and higher possible upside, research analysts clearly believe Immuneering is more favorable than Janux Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immuneering	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	3.00
Janux Therapeutics	2 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.67

67.7% of Immuneering shares are held by institutional investors. Comparatively, 75.4% of Janux Therapeutics shares are held by institutional investors. 14.9% of Immuneering shares are held by company insiders. Comparatively, 7.9% of Janux Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Immuneering has a beta of 0.4, meaning that its stock price is 60% less volatile than the broader market. Comparatively, Janux Therapeutics has a beta of 2.53, meaning that its stock price is 153% more volatile than the broader market.

In the previous week, Immuneering had 2 more articles in the media than Janux Therapeutics. MarketBeat recorded 6 mentions for Immuneering and 4 mentions for Janux Therapeutics. Janux Therapeutics' average media sentiment score of 1.36 beat Immuneering's score of -0.32 indicating that Janux Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immuneering	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	3 Very Negative mention(s)	Neutral
Janux Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Immuneering beats Janux Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Immuneering compare to Monte Rosa Therapeutics?

Immuneering (NASDAQ:IMRX) and Monte Rosa Therapeutics (NASDAQ:GLUE) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, institutional ownership, valuation, media sentiment, analyst recommendations, risk, profitability and earnings.

67.7% of Immuneering shares are owned by institutional investors. Comparatively, 80.0% of Monte Rosa Therapeutics shares are owned by institutional investors. 14.9% of Immuneering shares are owned by insiders. Comparatively, 6.4% of Monte Rosa Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Immuneering has a beta of 0.4, indicating that its stock price is 60% less volatile than the broader market. Comparatively, Monte Rosa Therapeutics has a beta of 1.5, indicating that its stock price is 50% more volatile than the broader market.

In the previous week, Monte Rosa Therapeutics had 2 more articles in the media than Immuneering. MarketBeat recorded 8 mentions for Monte Rosa Therapeutics and 6 mentions for Immuneering. Monte Rosa Therapeutics' average media sentiment score of 0.84 beat Immuneering's score of -0.32 indicating that Monte Rosa Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immuneering	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	3 Very Negative mention(s)	Neutral
Monte Rosa Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Immuneering currently has a consensus target price of $17.50, indicating a potential upside of 309.84%. Monte Rosa Therapeutics has a consensus target price of $28.50, indicating a potential upside of 102.56%. Given Immuneering's stronger consensus rating and higher possible upside, analysts plainly believe Immuneering is more favorable than Monte Rosa Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immuneering	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	3.00
Monte Rosa Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

Immuneering has a net margin of 0.00% compared to Monte Rosa Therapeutics' net margin of -560.85%. Immuneering's return on equity of -27.15% beat Monte Rosa Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immuneering	N/A	-27.15%	-25.75%
Monte Rosa Therapeutics	-560.85%	-43.31%	-27.59%

Monte Rosa Therapeutics has higher revenue and earnings than Immuneering. Monte Rosa Therapeutics is trading at a lower price-to-earnings ratio than Immuneering, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immuneering	N/A	N/A	-$56.03M	-$1.04	N/A
Monte Rosa Therapeutics	$123.67M	9.71	-$38.63M	-$1.76	N/A

Summary

Immuneering beats Monte Rosa Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Immuneering compare to Corvus Pharmaceuticals?

Immuneering (NASDAQ:IMRX) and Corvus Pharmaceuticals (NASDAQ:CRVS) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, valuation, dividends, analyst recommendations, profitability, media sentiment, institutional ownership and earnings.

Immuneering currently has a consensus price target of $17.50, indicating a potential upside of 309.84%. Corvus Pharmaceuticals has a consensus price target of $33.33, indicating a potential upside of 158.20%. Given Immuneering's stronger consensus rating and higher possible upside, research analysts clearly believe Immuneering is more favorable than Corvus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immuneering	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	3.00
Corvus Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

Immuneering's return on equity of -27.15% beat Corvus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immuneering	N/A	-27.15%	-25.75%
Corvus Pharmaceuticals	N/A	-36.15%	-33.62%

Immuneering has a beta of 0.4, meaning that its share price is 60% less volatile than the broader market. Comparatively, Corvus Pharmaceuticals has a beta of 0.87, meaning that its share price is 13% less volatile than the broader market.

67.7% of Immuneering shares are owned by institutional investors. Comparatively, 46.6% of Corvus Pharmaceuticals shares are owned by institutional investors. 14.9% of Immuneering shares are owned by insiders. Comparatively, 19.7% of Corvus Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Corvus Pharmaceuticals is trading at a lower price-to-earnings ratio than Immuneering, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immuneering	N/A	N/A	-$56.03M	-$1.04	N/A
Corvus Pharmaceuticals	N/A	N/A	-$15.28M	-$0.61	N/A

In the previous week, Immuneering had 4 more articles in the media than Corvus Pharmaceuticals. MarketBeat recorded 6 mentions for Immuneering and 2 mentions for Corvus Pharmaceuticals. Corvus Pharmaceuticals' average media sentiment score of 1.70 beat Immuneering's score of -0.32 indicating that Corvus Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immuneering	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	3 Very Negative mention(s)	Neutral
Corvus Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

Immuneering beats Corvus Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

How does Immuneering compare to Savara?

Savara (NASDAQ:SVRA) and Immuneering (NASDAQ:IMRX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, risk, institutional ownership, profitability, analyst recommendations, valuation and dividends.

Savara has a beta of 0.25, suggesting that its stock price is 75% less volatile than the broader market. Comparatively, Immuneering has a beta of 0.4, suggesting that its stock price is 60% less volatile than the broader market.

In the previous week, Immuneering had 4 more articles in the media than Savara. MarketBeat recorded 6 mentions for Immuneering and 2 mentions for Savara. Savara's average media sentiment score of 1.84 beat Immuneering's score of -0.32 indicating that Savara is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Savara	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Immuneering	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	3 Very Negative mention(s)	Neutral

Savara currently has a consensus price target of $10.00, suggesting a potential upside of 88.68%. Immuneering has a consensus price target of $17.50, suggesting a potential upside of 309.84%. Given Immuneering's stronger consensus rating and higher probable upside, analysts plainly believe Immuneering is more favorable than Savara.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Savara	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Immuneering	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	3.00

87.9% of Savara shares are owned by institutional investors. Comparatively, 67.7% of Immuneering shares are owned by institutional investors. 5.3% of Savara shares are owned by insiders. Comparatively, 14.9% of Immuneering shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Savara is trading at a lower price-to-earnings ratio than Immuneering, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Savara	N/A	N/A	-$118.84M	-$0.58	N/A
Immuneering	N/A	N/A	-$56.03M	-$1.04	N/A

Immuneering's return on equity of -27.15% beat Savara's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Savara	N/A	-90.28%	-68.95%
Immuneering	N/A	-27.15%	-25.75%

Summary

Immuneering beats Savara on 10 of the 14 factors compared between the two stocks.

How does Immuneering compare to Kura Oncology?

Immuneering (NASDAQ:IMRX) and Kura Oncology (NASDAQ:KURA) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their earnings, valuation, risk, institutional ownership, dividends, profitability, media sentiment and analyst recommendations.

In the previous week, Kura Oncology had 2 more articles in the media than Immuneering. MarketBeat recorded 8 mentions for Kura Oncology and 6 mentions for Immuneering. Kura Oncology's average media sentiment score of 0.43 beat Immuneering's score of -0.32 indicating that Kura Oncology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immuneering	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	3 Very Negative mention(s)	Neutral
Kura Oncology	1 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Immuneering has a net margin of 0.00% compared to Kura Oncology's net margin of -384.30%. Immuneering's return on equity of -27.15% beat Kura Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immuneering	N/A	-27.15%	-25.75%
Kura Oncology	-384.30%	-207.18%	-45.17%

Immuneering presently has a consensus price target of $17.50, suggesting a potential upside of 309.84%. Kura Oncology has a consensus price target of $25.40, suggesting a potential upside of 123.00%. Given Immuneering's stronger consensus rating and higher possible upside, analysts plainly believe Immuneering is more favorable than Kura Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immuneering	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	3.00
Kura Oncology	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

67.7% of Immuneering shares are owned by institutional investors. 14.9% of Immuneering shares are owned by company insiders. Comparatively, 7.6% of Kura Oncology shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Immuneering has higher earnings, but lower revenue than Kura Oncology. Immuneering is trading at a lower price-to-earnings ratio than Kura Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immuneering	N/A	N/A	-$56.03M	-$1.04	N/A
Kura Oncology	$67.48M	15.02	-$278.67M	-$3.37	N/A

Immuneering has a beta of 0.4, suggesting that its share price is 60% less volatile than the broader market. Comparatively, Kura Oncology has a beta of 0.44, suggesting that its share price is 56% less volatile than the broader market.

Summary

Immuneering beats Kura Oncology on 10 of the 16 factors compared between the two stocks.

Get Immuneering News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IMRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IMRX vs. The Competition

Export

Metric	Immuneering	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$276.26M	$3.85B	$7.16B	$12.85B
Dividend Yield	N/A	3.65%	2.57%	11.17%
P/E Ratio	-4.11	14.18	274.94	25.36
Price / Sales	N/A	1,374.99	686.01	116.83
Price / Cash	N/A	106.50	76.65	51.52
Price / Book	1.26	15.12	10.33	6.20
Net Income	-$56.03M	-$22.86M	$3.50B	$358.50M
7 Day Performance	-11.41%	-4.34%	-3.32%	-2.35%
1 Month Performance	-17.88%	0.54%	-0.53%	-3.23%
1 Year Performance	-49.71%	40.74%	23.51%	8.79%

Immuneering Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IMRX Immuneering	2.6753 of 5 stars	$4.27 -6.6%	$17.50 +309.8%	-49.7%	$276.26M	N/A	N/A	60	News Coverage
JANX Janux Therapeutics	3.417 of 5 stars	$20.01 -1.1%	$36.46 +82.2%	-28.9%	$1.22B	$10M	N/A	30	Positive News Gap Down
GLUE Monte Rosa Therapeutics	2.4799 of 5 stars	$14.15 +2.2%	$28.50 +101.5%	+192.5%	$1.21B	$123.67M	N/A	90	Analyst Forecast
CRVS Corvus Pharmaceuticals	2.3177 of 5 stars	$14.00 -2.7%	$33.33 +138.1%	+121.4%	$1.18B	N/A	N/A	30	Positive News Gap Down
SVRA Savara	2.1503 of 5 stars	$5.61 +4.4%	$10.14 +81.0%	+48.9%	$1.15B	N/A	N/A	20	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IMRX) was last updated on 9/13/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Immuneering (IMRX) Competitors

IMRX vs. JANX, GLUE, CRVS, SVRA, and KURA

How does Immuneering compare to Janux Therapeutics?

Summary

How does Immuneering compare to Monte Rosa Therapeutics?

Summary

How does Immuneering compare to Corvus Pharmaceuticals?

Summary

How does Immuneering compare to Savara?

Summary

How does Immuneering compare to Kura Oncology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMRX vs. The Competition

Immuneering Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Immuneering (IMRX) Competitors

IMRX vs. JANX, GLUE, CRVS, SVRA, and KURA

How does Immuneering compare to Janux Therapeutics?

Which has stronger earnings & valuation, IMRX or JANX?

Is IMRX or JANX more profitable?

Do analysts recommend IMRX or JANX?

Do institutionals & insiders hold more shares of IMRX or JANX?

Which has more volatility and risk, IMRX or JANX?

Does the media refer more to IMRX or JANX?

Summary

How does Immuneering compare to Monte Rosa Therapeutics?

Do institutionals & insiders believe in IMRX or GLUE?

Which has more risk & volatility, IMRX or GLUE?

Does the media refer more to IMRX or GLUE?

Do analysts rate IMRX or GLUE?

Is IMRX or GLUE more profitable?

Which has higher earnings and valuation, IMRX or GLUE?

Summary

How does Immuneering compare to Corvus Pharmaceuticals?

Do analysts rate IMRX or CRVS?

Is IMRX or CRVS more profitable?

Which has more risk and volatility, IMRX or CRVS?

Do institutionals and insiders believe in IMRX or CRVS?

Which has better valuation and earnings, IMRX or CRVS?

Does the media favor IMRX or CRVS?

Summary

How does Immuneering compare to Savara?

Which has more volatility and risk, SVRA or IMRX?

Does the media prefer SVRA or IMRX?

Do analysts recommend SVRA or IMRX?

Do institutionals & insiders have more ownership in SVRA or IMRX?

Which has stronger earnings & valuation, SVRA or IMRX?

Is SVRA or IMRX more profitable?

Summary

How does Immuneering compare to Kura Oncology?

Does the media prefer IMRX or KURA?

Is IMRX or KURA more profitable?

Do analysts recommend IMRX or KURA?

Do insiders & institutionals have more ownership in IMRX or KURA?

Which has better valuation & earnings, IMRX or KURA?

Which has more volatility & risk, IMRX or KURA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMRX vs. The Competition

Immuneering Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools